Login to Your Account



Amgen's Cinacalcet Gains FDA Nod For SHPT In Kidney Patients

By Randall Osborne


Wednesday, March 10, 2004
Amgen Inc. gained FDA approval of cinacalcet as a treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis and for hypercalcemia in those with parathyroid carcinoma - and NPS Pharmaceuticals Inc. gained a $10 million milestone payment as part of their licensing deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription